
    
      Considering the reduced CFR and increased platelet aggregability in patients with MVA,
      together with the augmented effect on adenosine-mediated coronary blood flow and potent
      antiplatelet effect of ticagrelor, we speculate that ticagrelor can promisingly ameliorate
      the coronary microvascular function in patients with MVA.
    
  